Desidustat Tablets Being Granted an Approval for Drug Clinical Trial
2021-01-19 20:43

China Medical System Holdings Limited (the ¡°Company¡±, together with its subsidiaries, the ¡°Group¡±) is pleased to announce that Desidustat Tablets of the Group licensed in from Cadila Healthcare Limited (¡°Zydus¡±) on 20 January 2020, has been granted an approval for drug clinical trial issued on 18 January 2021 from the National Medical Products Administration of the People¡¯s Republic of China and agreed to carry out clinical trials for indication of anemia (including dialysis and non-dialysis patients) caused by chronic kidney disease (CKD) .

Desidustat Tablets are novel oral Hypoxia-inducible factor-prolyl hydroxylase inhibitors (HIF-PHI) for treating anemia in CKD patients. 

The Group is currently actively preparing for initiating the relevant clinical trials.